Eli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2 diabetes, making it the first country in Europe where the treatment is available.The pill, known chemically as orforglipron, will be available via private prescription after Britain's medicines regulator authorised the drug on August 10, making it the second GLP-1 oral pill to be cleared in the UK after Novo Nordisk's Wegovy.Lilly said it was working with England's health cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), on a potential roll-out at the state-run National Health Service.Also read: Paramount-Warner Bros merger: California may seek cable channel divestitures, film studio safeguardsLilly said Foundayo will likely be priced between £100 and £120, lower than its Mounjaro injection's £330 for a month's supply.Foundayo remains under review in the European Union, while Novo's Wegovy pill has won a positive recommendation from the European Medicines Agency, with a final decision from the European Commission pending.
Eli Lilly launches oral weight-loss pill Foundayo in UK
Eli Lilly has launched its oral weight management pill Foundayo in the United Kingdom. This new treatment, chemically known as orforglipron, is available via private prescription. Britain's medicines regulator authorized the drug on August 10, making it the second oral GLP-1 pill cleared. Foundayo is expected to be priced between £100 and £120 per month.
163 words~1 min read
